[Abstract unavailable

Control of tuberculosis worldwide depends on our understanding of human immune mechanisms, which combat the infection. Acquired T cell responses are critical for host defense against microbial pathogens, yet the mechanisms by which they act in humans remain unclear. We report that T cells, by the release of interferon-γ (IFN-γ), induce autophagy, phagosomal maturation, the production of antimicrobial peptides such as cathelicidin, and antimicrobial activity against Mycobacterium tuberculosis in human macrophages via a vitamin D–dependent pathway. IFN-γ induced the antimicrobial pathway in human macrophages cultured in vitamin D–sufficient sera, but not in sera from African-Americans that have lower amounts of vitamin D and who are more susceptible to tuberculosis. In vitro supplementation of vitamin D–deficient serum with 25-hydroxyvitamin D3 restored IFN-γ–induced antimicrobial peptide expression, autophagy, phagosome-lysosome fusion, and antimicrobial activity. These results suggest a mechanism in which vitamin D is required for acquired immunity to overcome the ability of intracellular pathogens to evade macrophage-mediated antimicrobial responses. The present findings underscore the importance of adequate amounts of vitamin D in all human populations for sustaining both innate and acquired immunity against infection.

We investigated the mechanisms by which T-cell cytokines are able to influence the Toll-like receptor (TLR)-induced, vitamin Ddependent antimicrobial pathway in human monocytes. T-cell cytokines differentially influenced TLR2/1-induced expression of the antimicrobial peptides cathelicidin and DEFB4, being upregulated by IFN-γ, down-regulated by IL-4, and unaffected by IL-17. The Th1 cytokine IFN-γ up-regulated TLR2/1 induction of 25-hydroxyvitamin D-1α-hydroxylase (i.e., CYP27B1), leading to enhanced bioconversion of 25-hydroxyvitamin D 3 (25D 3 ) to its active metabolite 1,25D 3 . In contrast, the Th2 cytokine IL-4, by itself and in combination with the TLR2/1 ligand, induced catabolism of 25D 3 to the inactive metabolite 24,25D 3 , and was dependent on expression of vitamin D-24-hydroxylase (i.e., CYP24A1). Therefore, the ability of T-cell cytokines to differentially control monocyte vitamin D metabolism represents a mechanism by which cell-mediated immune responses can regulate innate immune mechanisms to defend against microbial pathogens. Mycobacterium tuberculosisT he ability of Toll-like receptors (TLRs) to trigger a direct antimicrobial activity is a key aspect of their role in innate immunity. In mouse monocytes, activation of the TLR2/1 heterodimer by microbial lipoproteins (1-3), induces an antimicrobial activity against Mycobacterium tuberculosis that is nitric oxide (NO)-dependent, but in human monocytes is NO-independent (4). Instead, a key antimicrobial mechanism for TLR-activated human monocytes involves induction of the 25-hydroxyvitamin D-1α-hydroxylase (i.e., CYP27B1), which enzymatically converts the major circulating form of vitamin D, 25-hydroxyvitamin D3 (25D 3 ) into the active form of vitamin D, 1,25D 3 . Parallel TLRmediated up-regulation of the vitamin D receptor (VDR) and activation of this receptor by 1,25D 3 leads to downstream induction of the genes encoding the antimicrobial peptides cathelicidin and DEFB4 (5-10). Here, we tested the hypothesis that adaptive T-cell cytokines, including key cytokines of the Th1, Th2, and Th17 pattern, regulate the TLR2/1-induced, vitamin Ddependent antimicrobial pathway. ResultsEffect of T-Cell Cytokines on TLR2/1 Induction of Cathelicidin and DEFB4. To determine the role of individual cytokines on the TLRtriggered vitamin D-dependent induction of antimicrobial peptides, monocytes were treated with TLR2/1L with or without a specific T-cell cytokine, and cathelicidin and DEFB4 mRNAs measured at 24 h. IFN-γ by itself up-regulated cathelicidin and DEFB4 mRNA levels by twofold ( Fig. 1A; P < 0.05 and P < 0.001). Consistent with previous findings, TLR2/1L induced both cathelicidin and DEFB4 mRNAs (8, 10). However, whereas IFN-γ augmented TLR2/1L-triggered induction of cathelicidin by 4.1-fold (P < 0.01), it had no effect on TLR2/1L-mediated induction of DEFB4 (Fig. 1A). The addition of IL-17 had no effect on induction of antimicrobial peptide gene expression in the presence or absence of TLR2/1L (Fig. 1B).Whereas IFN-γ augmented TLR2/1 induction of cath...

The mechanisms that regulate the acidification of intracellular compartments are key to host defense against pathogens. In this paper, we demonstrate that Abl tyrosine kinase, a master switch for cell growth and trafficking of intracellular organelles, controls the acidification of lysosomes in human macrophages. Pharmacological inhibition by imatinib and gene silencing of Abelson (Abl) tyrosine kinase reduced the lysosomal pH in human macrophages by increasing the transcription and expression of the proton pumping enzyme vacuolar-type H+-adenosine triphosphatase. Because lysosomal acidification is required for antimicrobial activity against intracellular bacteria, we determined the effect of imatinib on the growth of the major human pathogen Mycobacterium tuberculosis. Imatinib limited the multiplication of M. tuberculosis. and growth restriction was dependent on acidification of the mycobacterial compartment. The effects of imatinib were also active in vivo because circulating monocytes from imatinibtreated leukemia patients were more acidic than monocytes from control donors. Importantly, sera from imatinib-treated patients triggered acidification and growth restriction of M. tuberculosis in macrophages. In summary, our results identify the control of phagosomal acidification as a novel function of Abl tyrosine kinase and provide evidence that the regulation occurs on the level of the vacuolar-type H+-adenosine triphosphatase. Given the efficacy of imatinib in a mouse model of tuberculosis and our finding that orally administered imatinib increased the ability of human serum to trigger growth reduction of intracellular M. tuberculosis, clinical evaluation of imatinib as a complementary therapy of tuberculosis, in particular multidrug or extremely drugresistant disease, is warranted.

No abstract